000141687 001__ 141687
000141687 005__ 20240229105129.0
000141687 0247_ $$2doi$$a10.1186/s12885-018-4992-3
000141687 0247_ $$2pmid$$apmid:30400840
000141687 0247_ $$2pmc$$apmc:PMC6220507
000141687 0247_ $$2altmetric$$aaltmetric:50988262
000141687 037__ $$aDKFZ-2018-01958
000141687 041__ $$aeng
000141687 082__ $$a610
000141687 1001_ $$aOberste, Max$$b0
000141687 245__ $$aProtocol for the 'Chemobrain in Motion - study' (CIM - study): a randomized placebo-controlled trial of the impact of a high-intensity interval endurance training on cancer related cognitive impairments in women with breast cancer receiving first-line chemotherapy.
000141687 260__ $$aHeidelberg$$bSpringer$$c2018
000141687 3367_ $$2DRIVER$$aarticle
000141687 3367_ $$2DataCite$$aOutput Types/Journal article
000141687 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1542957008_22861
000141687 3367_ $$2BibTeX$$aARTICLE
000141687 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000141687 3367_ $$00$$2EndNote$$aJournal Article
000141687 520__ $$aUp to 80% of breast cancer patients suffer from Cancer Related Cognitive Impairments (CRCI). Exercise is suggested as a potential supportive care option to reduce cognitive decline in cancer patients. This study will investigate the effects of a high-intensity interval endurance training (HIIT) on CRCI in breast cancer patients. Potentially underlying immunological and neurobiological mechanisms, as well as effects on patients' self-perceived cognitive functioning and common cancer related side-effects, will be explored.A single-blinded randomized controlled trial will be carried out. The impact of HIIT on CRCI will be compared to that of a placebo-intervention (supervised myofascial release training). Both interventions will be conducted simultaneously with the patients' first-line chemotherapy treatment typically lasting 12-18 weeks. Fifty-nine women with breast cancer will be included in each of the two groups. The study is powered to detect (α = .05, β = .2) a medium effect size difference between the two groups (d = .5) in terms of patients' change in cognitive testing performances, from baseline until the end of the exercise-intervention. The cognitive test battery, recommended by the International Cancer and Cognition Task Force to assess CRCI, will be used as primary measure. This includes the Hopkins Verbal Learning Test (learning/verbal memory), the Controlled Oral Word Association Test (verbal fluency) and the Trail-Making-Test A/B (attention/set-switching). The following endpoints will be assessed as secondary measures: Go-/No-Go test performance (response inhibition), self-perceived cognitive functioning, serum levels of pro- and antiinflammatory markers (tumor necrosis factor alpha, Interleukin-6, Interleukin-1 alpha, Interleukin-1 beta, C-reactive protein, Interleukin-1 receptor antagonist and Interleukin-10), serum levels of neurotrophic and growth factors (brain-derived neurotrophic factor, insulin-like growth factor 1 and vascular endothelial growth factor), as well as common cancer-related side effects (decrease in physical capacity, fatigue, anxiety and depression, sleep disturbances, quality of life and chemotherapy compliance).This study will provide data on the question whether HIIT is an effective supportive therapy that alleviates CRCI in breast cancer patients. Moreover, the present study will help shed light on the underlying mechanisms of potential CRCI improving effects of exercise in breast cancer patients.DRKS.de, German Clinical Trials Register (DRKS), ID: DRKS00011390 , Registered on 17 January 2018.
000141687 536__ $$0G:(DE-HGF)POF3-317$$a317 - Translational cancer research (POF3-317)$$cPOF3-317$$fPOF III$$x0
000141687 588__ $$aDataset connected to CrossRef, PubMed,
000141687 7001_ $$aSchaffrath, Nils$$b1
000141687 7001_ $$aSchmidt, Katharina$$b2
000141687 7001_ $$aBloch, Wilhelm$$b3
000141687 7001_ $$aJäger, Elke$$b4
000141687 7001_ $$0P:(DE-He78)a0c2037d9054be26907a05ae520d5756$$aSteindorf, Karen$$b5$$udkfz
000141687 7001_ $$aHartig, Philipp$$b6
000141687 7001_ $$aJoisten, Niklas$$b7
000141687 7001_ $$0P:(DE-He78)d05b24af674d8ef2c455634434b67770$$aZimmer, Philipp$$b8$$eLast author$$udkfz
000141687 773__ $$0PERI:(DE-600)2041352-X$$a10.1186/s12885-018-4992-3$$gVol. 18, no. 1, p. 1071$$n1$$p1071$$tBMC cancer$$v18$$x1471-2407$$y2018
000141687 909CO $$ooai:inrepo02.dkfz.de:141687$$pVDB
000141687 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)a0c2037d9054be26907a05ae520d5756$$aDeutsches Krebsforschungszentrum$$b5$$kDKFZ
000141687 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)d05b24af674d8ef2c455634434b67770$$aDeutsches Krebsforschungszentrum$$b8$$kDKFZ
000141687 9131_ $$0G:(DE-HGF)POF3-317$$1G:(DE-HGF)POF3-310$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vTranslational cancer research$$x0
000141687 9141_ $$y2018
000141687 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bBMC CANCER : 2017
000141687 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS
000141687 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline
000141687 915__ $$0StatID:(DE-HGF)0310$$2StatID$$aDBCoverage$$bNCBI Molecular Biology Database
000141687 915__ $$0StatID:(DE-HGF)0320$$2StatID$$aDBCoverage$$bPubMed Central
000141687 915__ $$0StatID:(DE-HGF)0501$$2StatID$$aDBCoverage$$bDOAJ Seal
000141687 915__ $$0StatID:(DE-HGF)0500$$2StatID$$aDBCoverage$$bDOAJ
000141687 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bDOAJ : Open peer review
000141687 915__ $$0LIC:(DE-HGF)CCBYNV$$2V:(DE-HGF)$$aCreative Commons Attribution CC BY (No Version)$$bDOAJ
000141687 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search
000141687 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC
000141687 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List
000141687 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded
000141687 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection
000141687 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine
000141687 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5
000141687 9201_ $$0I:(DE-He78)G210-20160331$$kG210$$lBewegung, Präventionsforschung und Krebs$$x0
000141687 980__ $$ajournal
000141687 980__ $$aVDB
000141687 980__ $$aI:(DE-He78)G210-20160331
000141687 980__ $$aUNRESTRICTED